Kinase inhibitors for advanced medullary thyroid carcinoma

Clinics

Volumn 67, Issue SUPPLEMENT, 2012, Pages 125-129

  Schlumberger, Martin ^a   Massicotte, Marie Hélène ^a   Nascimento, Camila L ^a   Chougnet, Cécile ^a   Baudin, Eric ^a   Leboulleux, Sophie ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Molecular Targeted Therapy; Thyroid Neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 ((1 METHYLPIPERIDIN 4 YL)METHOXY)QUINAZOLIN 4 AMINE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOL IN-4-AMINE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

CLINICAL TRIAL (TOPIC); HUMAN; MEDULLARY CARCINOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PATIENT SELECTION; REVIEW; STANDARD; THYROID TUMOR;

ANTINEOPLASTIC AGENTS; CARCINOMA, MEDULLARY; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; PATIENT SELECTION; PIPERIDINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; THYROID NEOPLASMS;

EID: 84863906261     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(Sup01)21     Document Type: Review

References (37)

1. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19:565-612, http://dx.doi.org/10.1089/thy.2008.0403.
2. Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2008;4:22-32, http://dx.doi.org/10.1038/ncpendmet0717.
3. Giraudet AL, Vanel D, Leboulleux S, Aupérin A, Dromain C, Chami L, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007;92:4185-90. Epub 2007 Aug 28, http://dx.doi.org/10.1210/jc.2007-1211
4. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47, http://dx.doi.org/10.1016/j.ejca.2008.10.026.
5. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16, http://dx.doi.org/10.1093/jnci/92.3.205.
6. Laure Giraudet A, Al Ghulzan A, Aupérin A, Leboulleux S, Chehboun A, Troalen F, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol. 2008;158:239-46, http://dx.doi.org/10.1530/EJE-07-0667.
7. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:6077-84, http://dx.doi.org/10.1210/jc.2005-0044.
8. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985;56:2155-60, http://dx.doi.org/10.1002/1097-0142(19851101)56:9,2155::AIDCNCR2820560903.3.0. CO;2-E.
9. Williams SD, Birch R, Einhorn LH. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep. 1986;70:405-7.
10. Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany-Corone C, Schlumberger M, et al. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FUdacarbazine. Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer. 2000;83:715-8, http://dx.doi.org/10.1054/bjoc.2000.1314.
11. Kraeber-Bodere F, Goldenberg DM, Chatal JF, Barbet J. Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer. Curr Oncol. 2009;16:3-8.
12. Iten F, Müller B, Schindler C, Rochlitz C, Oertli D, Mäcke HR, et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with longterm survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res. 2007;13:6696-702, http://dx.doi.org/10.1158/1078-0432.CCR-07-0935.
13. Papewalis C, Wuttke M, Seissler J, Meyer Y, Kessler C, Jacobs B, et al. Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer. Clin Cancer Res. 2008;14:4298-305, http://dx.doi.org/10.1158/1078-0432.CCR-08-0587.
14. Wells SA Jr, Santoro M. Targeting the RET pathway in thyroid cancer. Clin Cancer Res. 2009;15:7119-23, http://dx.doi.org/10.1158/1078-0432.CCR-08-2742.
15. Moura MM, Cavaco BM, Pinto AE, Leite V. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab. 2011;96:863-8, http://dx.doi.org/10.1210/jc.2010-1921.
16. Papotti M, Olivero M, Volante M, Negro F, Prat M, Comoglio PM, et al. Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocr Pathol. 2000;11:19-30, http://dx.doi.org/10.1385/EP:11:1:19.
17. Capp C, Wajner SM, Siqueira DR, Brasil BA, Meurer L, Maia AL. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid. 2010;20:863-71, http://dx.doi.org/10.1089/thy.2009.0417.
18. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients With medullary thyroid cancer. J Clin Oncol. 2011;29:2660-6. Epub 2011 May 23, http://dx.doi.org/10.1200/JCO.2010.32.4145
19. Tuttle RM, Ball DW, Byrd D, Daniels GH, Dilawari RA, Doherty GM, et al. Medullary carcinoma. J Natl Compr Canc Netw. 2010;8:512-30.
20. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28:767-72. Epub 2010 Jan 11, http://dx.doi.org/10.1200/JCO.2009. 23.6604
21. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2664-71. Epub 2010 Apr 6, http://dx.doi.org/10.1210/jc.2009-2461
22. Wells SA, Robinson BG, Gagel RF, Dralle H. Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind phase III trial (ZETA). J Clin Oncol. 2010;28(15 Suppl):5503.
23. Akeno-Stuart N, Croyle M, Knauf JA, Malaguarnera R, Vitagliano D, Santoro M, et al. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res. 2007;67:6956-64, http://dx.doi.org/10.1158/0008-5472.CAN-06-4605.
24. Schlumberger M, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati L, et al. Phase II study of safety and efficacy ofmotesanib(AMG706) in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009;27:3794-801, http://dx.doi.org/10.1200/JCO.2008.18.7815.
25. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010;28:2323-30, http://dx.doi.org/10.1200/JCO.2009. 25.0068.
26. Kober F, Hermann M, Handler A, Krotla G. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer. J Clin Oncol. 2007;25(18 Suppl):14065.
27. Cabanillas ME, Kurzrock R, Sherman SI, Tsimberidou AM, Waguespack S, Naing AN, et al. Phase I trial of combination sorafenib and tipifarnib: the experience in advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). J Clin Oncol. 2010;28(15 Suppl):5586.
28. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26:4708-13, http://dx.doi.org/10.1200/JCO.2007.15.9566.
29. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, et al. Phase II trial of sunitinib in medullary thyroid cancer (MTC). J Clin Oncol. 2008;26:4708-13. Epub 2008 Jun 9, http://dx.doi.org/10.1200/JCO.2007.15.9566
30. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16:5260-8. Epub 2010 Sep 16, http://dx.doi.org/10.1158/1078-0432. CCR-10-0994
31. Bible KC. Phase II trial of pazopanib in rapidly progressive, metastatic, medullary thyroid cancer. Thyroid (Meeting Abstracts). 2009;19:S110.
32. Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, et al. Phase I dose-escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2008;26:5511-7. Epub 2008 Oct 27, http://dx.doi.org/10.1200/JCO.2008.16.1547.
33. Frank-Raue K, Fabel M, Delorme S, Haberkorn U, Raue F. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol. 2007;157:215-20, http://dx.doi.org/10.1530/EJE-06-0695.
34. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ, et al. A phase-II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:3466-9, http://dx.doi.org/10.1210/jc.2007-0649.
35. Hoff PM, Hoff AO, Phanet AT, Sherman SI, Yao J, White N, et al. Phase I/II trial of capecitabine (C), dacarbazine (D) and imatinib (I) (CDI) for patients (pts) metastatic medullary thyroid carcinomas (MTC). J Clin Oncol. 2006;24(18 Suppl):13048.
36. Abdulrahman RM, Verloop H, Hoftijzer H, Verburg E, Hovens GC, Corssmit EP, et al. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab. 2010;95:3758-62, http://dx.doi.org/10.1210/jc.2009-2507.
37. Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, et al. Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab. 2009;94: 4423-32, http://dx.doi.org/10.1210/jc.2009-0743.